{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:30:15Z","timestamp":1788993015867,"version":"build-2803163510"},"reference-count":25,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>\n                      To investigate the phenotypic and genotypic profile of multidrug-resistant (MDR)\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB) clinical isolates with reference to second-line injectable drugs (SLIDs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 110 MTB isolates, recovered consecutively from confirmed MDR-TB patients between March and June 2016, were included in this study. Phenotypic drug susceptibility testing against SLIDs (Kanamycin, Amikacin, and Capreomycin) and Ofloxacin (OFX) was performed using the MGIT 960 system. For genotypic analysis, SLID\/(s) resistant (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200913) and susceptible isolates (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200926) were subjected to PCR and DNA sequencing for\n                      <jats:italic toggle=\"yes\">rrs<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">eis<\/jats:italic>\n                      (promoter region), and\n                      <jats:italic toggle=\"yes\">tly<\/jats:italic>\n                      A loci of MTB. Furthermore, the identified genetic mutations were analyzed with respect to its significance in detecting phenotypic resistance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>\n                      Among the 110 analyzed isolates, phenotypic resistance to OFX, SLIDs, and to both was 59.1%, 11.8%, and 10.0%, respectively. Out of a total 13 SLID\/(s) resistant isolates, 10 had mutations (including two novel mutations) in one or more of the targeted genes. Only one SLID susceptible MTB isolate showed mutation in the targeted region. In SLID resistant isolates, most frequent mutation detected was C-12T under\n                      <jats:italic toggle=\"yes\">eis<\/jats:italic>\n                      promoter region (46.1%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Mutations in\n                      <jats:italic toggle=\"yes\">rrs<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">eis,<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">tly<\/jats:italic>\n                      A loci together are important in predicting SLID resistance in MTB isolates. Future molecular epidemiology studies are needed to have more insight into frequency and clinical relevance of novel mutations identified in this study.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/mdr.2019.0215","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T10:59:46Z","timestamp":1582714786000},"page":"971-975","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Second Line Injectable Drug Resistance and Associated Genetic Mutations in Newly Diagnosed Cases of Multidrug-Resistant Tuberculosis"],"prefix":"10.1177","volume":"26","author":[{"given":"Vangala","family":"Ramakrishna","sequence":"first","affiliation":[{"name":"Department of Microbiology, King George's Medical University, Lucknow, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, King George's Medical University, Lucknow, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantanu","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Microbiology, King George's Medical University, Lucknow, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Microbiology, King George's Medical University, Lucknow, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"World Health Organization. 2018. Global Health Estimate 2016 Death by Cause Age Sex by Country and by Region 2000\u20132016. WHO Geneva Switzerland."},{"key":"e_1_3_4_3_2","first-page":"Switzerland","article-title":"Global Tuberculosis Report, 2018","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Global Tuberculosis Report, 2018. WHO,, Geneva, Switzerland.","journal-title":"WHO,"},{"key":"e_1_3_4_4_2","unstructured":"Ministry of Health and Family Welfare Government of India. 2018. Report of the First National Anti-Tuberculois Drug Resistance Survey 2014\u20132016. https:\/\/tbcindia.gov.in\/index1.php?page=1&ipp=All&lang=1&level=1&sublinkid=4869&lid=3131 (accessed February21 2020)."},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tube.2012.05.010","article-title":"Pre-XDR and XDR in MDR and ofloxacin and kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates","volume":"92","author":"Jain A.","year":"2012","unstructured":"Jain A., , Dixit P., , and Prasad R.. 2012. Pre-XDR and XDR in MDR and ofloxacin and kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates. Tuberculosis, 92:404\u2013406.","journal-title":"Tuberculosis"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/0971-5916.182625","article-title":"A study on pre-XDR and XDR tuberculosis and their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India","volume":"143","author":"Singhal P.","year":"2016","unstructured":"Singhal P., , Dixit P., , Singh P., , Jaiswal I., , Singh M., , and Jain A.. 2016. A study on pre-XDR and XDR tuberculosis and their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India. Indian J. Med. Res. 143:341.","journal-title":"Indian J. Med. Res"},{"key":"e_1_3_4_7_2","first-page":"Switzerland","article-title":"Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR\/RR-TB)","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR\/RR-TB). WHO,, Geneva, Switzerland.","journal-title":"WHO,"},{"key":"e_1_3_4_8_2","first-page":"Switzerland","article-title":"Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis (MDR-TB)","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis (MDR-TB). WHO,, Geneva, Switzerland.","journal-title":"WHO,"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics3030317"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"e33275","DOI":"10.1371\/journal.pone.0033275","article-title":"Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review","volume":"7","author":"Georghiou S.B.","year":"2012","unstructured":"Georghiou S.B., , Magana M., , Garfein R.S, , Catanzaro D.G, , Catanzaro A., , and Rodwell T.C.. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One, 7:e33275.","journal-title":"PLoS One"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1128\/JCM.01947-09","article-title":"Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant mycobacterium tuberculosis complex isolates","volume":"48","author":"Brossier F.","year":"2010","unstructured":"Brossier F., , Veziris N., , Aubry A., , Jarlier V., , and Sougakoff W.. 2010. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 48:1683\u20131689.","journal-title":"J. Clin. Microbiol"},{"key":"e_1_3_4_12_2","volume-title":"Mycobacterium tuberculosis","author":"Zaunbrecher M.A.","year":"2000","unstructured":"Zaunbrecher M.A., , Sikes R.D, , Metchock B., , Shinnick T.M, , and Posey J.E. 2009. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 106: 20004\u20132, 2000."},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/JCM.02059-14","article-title":"Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low level drug resistance than phenotypic Lowenstein-Jensen testing","volume":"53","author":"Chakravorty S.","year":"2015","unstructured":"Chakravorty S., , Lee J.S, , Cho E.J, , Roh S.S, , Smith L.E, , Lee J., , Kim C.T, , Via L.E, , Cho S.N, , Barry C.E, , and Alland D.. 2015. Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low level drug resistance than phenotypic Lowenstein-Jensen testing. J. Clin. Microbiol. 53:43\u201351.","journal-title":"J. Clin. Microbiol"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/jac\/dks178","article-title":"The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region","volume":"67","author":"Gikalo M.B.","year":"2012","unstructured":"Gikalo M.B., , Nosova E.Y, , Krylova L.Y, , and Moroz A.M.. 2012. The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region. J. Antimicrob. Chemother. 67:2107\u20132109.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.molcel.2006.05.044","article-title":"Capreomycin binds across the ribosomal subunit Interface using tlyA-encoded 2\u2032-O-methylations in 16S and 23S rRNAs","volume":"23","author":"Johansen S.K.","year":"2006","unstructured":"Johansen S.K., , Maus C.E, , Plikaytis B.B, , and Douthwaite S.. 2006. Capreomycin binds across the ribosomal subunit Interface using tlyA-encoded 2\u2032-O-methylations in 16S and 23S rRNAs. Mol. Cell. 23:173\u2013182.","journal-title":"Mol. Cell"},{"key":"e_1_3_4_16_2","first-page":"Switzerland","article-title":"MGIT\u2122 Procedure Manual 2006","author":"Siddiqi S. H.","year":"2006","unstructured":"Siddiqi S. H., , and Rusch-Gerdes S.. 2006. MGIT\u2122 Procedure Manual 2006. Foundation for Innovative New Diagnostics,, Geneva, Switzerland.","journal-title":"Foundation for Innovative New Diagnostics,"},{"key":"e_1_3_4_17_2","unstructured":"WHO. 2012. World Health Organization Global TB Programme. Updated Interim Critical Concentrations for First-line and Second-line DST. Available at www.stoptb.org\/wg\/gli\/assets\/documents\/Updated%20critical%20concentration%20table_1st%20and%202nd%20line%20drugs.pdf May (Last accessed September26 2019)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.32.10.2425-2433.1994"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1128\/AAC.00851-09","article-title":"High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene","volume":"53","author":"Jugheli L.","year":"2009","unstructured":"Jugheli L., , Bzekalava N., , de Rijk P., , Fissette K., , Portaels F., , and Rigouts L.. 2009. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob. Agents Chemother. 53:5064\u20135068.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/dks371","article-title":"From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition","volume":"68","author":"Perdig\u00e3o J.","year":"2012","unstructured":"Perdig\u00e3o J., , Macedo R., , Silva C., , Machado D., , Couto I., , Viveiros M., , Jordao L., , and Portugal I.. 2012. From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition. J. Antimicrob. Chemother. 68:27\u201333.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2180-14-165","article-title":"Molecular characterization of amikacin, kanamycin and capreomycin resistance in M\/XDR-TB strains isolated in Thailand","volume":"14","author":"Sowajassatakul A.","year":"2014","unstructured":"Sowajassatakul A., , Prammananan T., , Chaiprasert A., , Phunpruch S.. 2014. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M\/XDR-TB strains isolated in Thailand. BMC Microbiol. 14:165.","journal-title":"BMC Microbiol"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1128\/AAC.47.9.2971-2973.2003","article-title":"Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis","volume":"47","author":"Kr\u00fc\u00fcner A.","year":"2003","unstructured":"Kr\u00fc\u00fcner A., , Jureen P., , Levina K., , Ghebremichael S., , and Hoffner S.. 2003. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:2971\u20132973.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.tube.2015.10.012","article-title":"Novel mutations conferring resistance to kanamycin in Mycobacterium tuberculosis clinical isolates from Northern India","volume":"96","author":"Kaur S.","year":"2016","unstructured":"Kaur S., , Rana V., , Singh P., , Trivedi G., , Anand S., , Kaur A., , Gupta P., , Jain A., , and Sharma C.. 2016. Novel mutations conferring resistance to kanamycin in Mycobacterium tuberculosis clinical isolates from Northern India. Tuberculosis, 96:e101.","journal-title":"Tuberculosis"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijmyco.2015.09.001","article-title":"Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables","volume":"5","author":"Kambli P.","year":"2016","unstructured":"Kambli P., , Ajbani K., , Nikam C., , Sadani M., , Shetty A., , Udwadia Z., , Georghiou S.B, , Rodwell T.C, , Catanzaro A., , and Rodrigues C.. 2016. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. Int. J. Mycobacteriol. 5:1\u20136.","journal-title":"Int. J. Mycobacteriol"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5588\/ijtld.17.0663","article-title":"Diagnostic accuracy of genoType\u00ae MTBDRsl VER 2.0 in detecting second-line drug resistance to M. tuberculosis","volume":"22","author":"Yadav R.","year":"2018","unstructured":"Yadav R., , Saini A., , Kaur P., , Behera D., , and Sethi S.. Diagnostic accuracy of genoType\u00ae MTBDRsl VER 2.0 in detecting second-line drug resistance to M. tuberculosis. 2018. Int. J. Tuberc. Lung Dis. 22:419\u2013424.","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jac\/dkr109","article-title":"Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis","volume":"66","author":"Engstr\u00f6m A.","year":"2011","unstructured":"Engstr\u00f6m A., , Perskvist N., , Werngren J., , Hoffner S.E, , and Jur\u00e9en P.. 2011. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 66:1247\u20131254.","journal-title":"J. Antimicrob. Chemother"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0215","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0215","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:36:08Z","timestamp":1777667768000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2019.0215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1089\/mdr.2019.0215"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0215","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]}}}